"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
Patients receiving OPTISON should be instructed to inform their healthcare provider if they:
- have a congenital heart defect, or recent worsening of heart or lung conditions;
- have had reactions to blood, blood products, albumin or a prior OPTISON administration (see CONTRAINDICATIONS and WARNINGS);
- may be pregnant or are nursing an infant.
Last reviewed on RxList: 9/6/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Optison Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.